Background: Aim of this study is to evaluate the accuracy of the gated volumetric modulated arc therapy (VMAT/RapidArc) using 2D planar dosimetry, DynaLog files and COMPASS 3D dosimetry system. Materials and Methods: Pre-treatment quality assurance of 10 gated VMAT plans was verified using 2D array and COMPASS 3D dosimetry system. Advantage of COMPASS over 2D planar is that it provides the clinical consequence of error in treatment delivery. Measurements were performed for non-gated and different phase ga.ng window level (80%, 50%, 30% & 20%) to know the impact of ga.ng in VMAT dose delivery. Results: In 2D planar dosimetry, gamma agreement index (GAI) for all measurements were more than 95%. DynaLog file analysis shows the average devia.ons between actual and expected posi.ons of monitor units, gantry and mul.-leaf collimator. The STDVs MU and gantry posi.on were less than 0.10 MU and 0.33° respec.vely. Root mean square (RMS) of the devia.ons of all leaves were less than 0.58 mm. The results from COMPASS show that 3D dose volume parameters for ten pa.ents measured for different phase ga.ng window level were within the tolerance level of ±5%. Average 3D gamma of PTV and OAR's for different window level was less than 0.6. Conclusion: The results from this study show that gated VMAT delivery provided dose distribu.ons equivalent to non-gated delivery to within clinically acceptable limits and COMPASS along with Matrix Evolu.on can be effec.vely used for pretreatment verifica.on of gated VMAT plans.
INTRODUCTION
Advanced radiotherapy techniques such as intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy produces high conformal dose distribution compared to conventional two dimensional treatment techniques. These treatment techniques target radiation doses precisely to the shape of tumors, reducing toxicity and side-effects. But for tumors in the thorax and abdomen region, respiratory motion is a limiting factor, which will degrade the effectiveness of conformal radiotherapy (1, 2) .
Tumors and organs at risk (OAR's) in thorax and abdomen region move with respect to patient breathing cycle, which increases the planning target volume (PTV) margins thereby increasing the normal tissue complications. Various techniques have been proposed to compensate for tumor motion which includes motion encompassing methods, respiratory gating methods, breath-hold methods, forced shallow breathing with abdominal compression and real time tumor tracking (3) (4) (5) (6) . In the breath-hold method, the patient is asked to hold breath during the imaging and treatment. In the forced shallow breathing treatment method, a physical plate is placed and -ixed over the abdominal region to restrict breathing motion and thereby limits the excursion of targets and OAR's but this may cause great patient discomfort. Real time tracking technique follows the tumor dynamically with the radiation beam by adjusting the gantry head or multi-leaf collimators (MLC). Respiratory gating is commonly used technique, in which radiation is delivered within a particular portion of the patient's breathing cycle (3) .
RapidArc (Varian Medical Systems, Palo Alto, CA, USA) is a form of a VMAT, which produces highly conformal dose distribution by simultaneously changing MLC position, dose rate and gantry speed during patient treatment. Many studies have shown the technical feasibility and advantage of VMAT, especially in reducing the treatment time compare to -ixed -ield IMRT (7) (8) (9) (10) . In treatment machine the VMAT plan is decomposed into two groups of control parameters. The MLC positions as a function of gantry angle are sent to the MLC controller. The gantry angle as a function of cumulative MU (dose) is sent as a segmented treatment table to the clinac control system (11, 12) . In gated VMAT, when patient breathing portion was outside the window level, beam hold command was sent to dose delivery system by gating system, to interrupt electron injection in the accelerating waveguide. In-sequence, dose delivery system temporarily stops gantry and MLC movement. Due to complex delivery of gated VMAT, it is essential to evaluate and verify the accuracy of the system before its clinical use (1) .
Nicolini et al. (12) has shown the pre-clinical evaluation of respiratory-gated delivery of VMAT by using 2D planar dosimetry in homogeneous phantom. Traditional QA procedures (point and 2D planar dosimetry) are performed in a phantom and the criteria that can be used depend on limits of the applied technology, it is often dif-icult to quantify and interpret the results in terms of clinical impact for the patient. Benjamin et al. (13) shows, there is lack of correlation between gamma passing rates from 2D array and dose differences in critical anatomic regions of interest. The results provided by 2D planar dosimetry cannot be directly used to see the effects of the dose calculation/treatment delivery errors on the tumour dose or dose to the normal tissues inside the patient (14) . To address this issue, alternate QA techniques has been developed to verify the 3D dose distribution in a patient computed tomography (CT) scan by measuring -luence at different gantry angle using ion chamber matrix or electronic portal imaging device (EPID). COMPASS (IBA Dosimetry, Germany) (V3.0) is 3D dose veri-ication system which uses Matrix Evolution and able to reconstruct dose in phantom or patient CT. It consists of measurement-based dose reconstruction and model-based dose calculation.
In measurement based dose reconstruction, (i) Detector dose response is predicted from the patient treatment plan parameters. (ii) Measured dose response from the Matrix Evolution is than compared with predicted dose response. (iii)The difference between the predicted and measured response along with correction kernel was used to derive the reconstruction -luence. Finally reconstructed -luence is fed to the dose engine based on collapsed cone convolution/ superposition (CCC/S) algorithm for computation of 3D dose within the patient CT scan. The dose calculated from the reconstructed -luence is referred as "indirectly measured" (COMPASS measured). In model based dose calculations, COMPASS system compute dose in patient CT scan using inbuilt beam model. The purpose of the dose computation is to provide an independent cross-veri-ication of treatment planning system (TPS) calculated dose.
In addition, COMPASS has a facility to compare the 3D dose distribution and dose volume histograms (DVH) between measured and TPS calculated. There are limitations due to the reconstruction capabilities of COMPASS, chamber resolution of MatriXX Evolution and algorithm difference (20) . So COMPASS may slightly underestimate and/or overestimate the actual delivered dose for PTV and OAR's. Despite local inaccuracies in the dose reconstruction, Godart et al. (17) have shown that COMPASS system was adequate to perform pretreatment veri-ication of VMAT treatment plans. Few studies have shown the experimental and clinical validation of COMPASS system for both IMRT and VMAT (14) (15) (16) (17) (18) (19) . In this study, we have evaluated the performance of gated volumetric modulated arc therapy by using 2D planar dosimetry, DynaLog Files and COMPASS 3D dosimetry system.
MATERIALS AND METHODS
10 Thorax VMAT plans with two arcs were chosen for this study. Selected cases were pooled from advanced stage (III) lung cancer with a dose prescription of 5000cGy in 25 fractions (Phase-I). The patients mean age was 52.4 years, 57.4% was male and 56.2% patient's tumour was seen on right lung. These patients were immobilized using thermoplastic mask in supine position with both the arms lifted above head on a hemi-body vaclock. Normal free-breathing scan of 3mm slice thicknesses were taken on a Biograph 16 Slice PET-CT scanner (Siemens Medical Systems Concord, CA). After CT scan, the DICOM images were transferred to Eclipse treatment planning system (V8.9) (Varian Medical Systems, Palo Alto, CA, USA) for contouring and planning. VMAT plans were optimized in Eclipse TPS (V8.9) using Progressive Resolution Optimizer -II (PRO) and -inal dose calculations were performed using Analytical Anisotropic Algorithm (AAA) with 2.5 mm grid resolution (19) . These ten patients were treated in normal free breathing using 6 MV photon beam from dual energy Clinac-iX (Varian Medical Systems, Palo Alto, USA). The machine was equipped with millennium 120 multi-leaf collimator, on-board imager and maximum dose rate of 600 MU/min. These ten patients CT data and treatment plans were used to appraise the feasibility and the dosimetric accuracy of gated VMAT. As this was primarily a dosimetric study, where patients were actually treated in free breathing VMAT, dosimetric analysis measurement were performed in phantom and gating was realized by means of the Real-time Position Management (RPM) system from Varian. RPM respiratory gating system consists of a marker block, an infrared (IR) light ring that emits IR light, a charge-coupled detector (CCD) as a tracking camera used to visualize the relative position of the block, and a workstation that displays and records the motion data as a waveform. The markers box will be placed on the patient's anterior abdominal surface, typically midway between the xyphoid process and the umbilicus. The position of placement must be carefully chosen to maximize the amplitude of the marker motion on the patient. The six re-lective -iducial markers were tracked using the IR light source and CCD detector. The six re-lecting dots allow the reconstruction of the 3D movements induced by the respiration cycle. In this method, motion of the block was considered as a surrogate for respiratoryinduced tumor motion.
To produce the respiratory cycle for our experiment, six dot re-lecting marker box was placed on a motion phantom (Varian). It has an elliptical wheel rotating according to a cycle period proportional to the variable voltage applied to the motor driving the wheel. The infrared camera mounted in the treatment room and a workstation converts re-lective signals from six markers into respiratory cycle. In respiratory gating, radiation is only delivered in a pre-set window called the "gating window" (-igure 1). The gating window can set either in amplitude based or phase based in the desired portion of the respiratory cycle. This gating window determines the radiation beam to on only during a pre-speci-ied part of the respiratory cycle. Measurements were performed for non-gated and four different phase based gating window level (PGWL) (80%, 50%, 30% and 20%) of respiratory cycle (-igure 1), i.e., number of interruptions were approximately increased from 5 to 20 times per arc and same were compared with Eclipse TPS calculated dose (performed without any gating). The variations of the duty cycle (the four different phases) were performed on the same respiratory cycle by taking different part of the breathing wave. 
2D Planar dosimetry
For 2D planar dosimetry, multicube phantom with MatriXX Evolution was CT scanned. MatriXX Evolution contains 1020 parallel plane ion chambers (32×32 matrix) with an active area of 24.4 cm ×24.4 cm having 7.62 mm resolution at isocenter 100 cm. To assess the VMAT delivery quality in pre-treatment QA context, veri-ication plans were created on this multicube phantom. In treatment delivery, multicube phantom was placed on couch and infrared re-lecting box was periodically moved to provide gating signal for RPM system (-igure 2a). To compare measurements and calculations, planar dose distribution at isocenter level from Eclipse TPS was exported to Omnipro IMRT software (V1.6) (IBA Dosimetry, Germany). To evaluate the agreement between Eclipse TPS calculated and MatriXX Evolution measured, the global gamma analysis were performed with criteria of 3mm distance to agreement (DTA) and 3% dose difference (DD). To check the reproducibility, measurement of one VMAT plan for -ive different duty cycles were performed for -ive consecutive days (with the complete setup of phantom and detectors every time). Statistical analyses were performed using the Student's t-test (paired, two-tailed) and differences were considered to be signi-icant for p-value < 0.05.
VMAT DynaLog !iles
During the VMAT dose delivery, the linac control systems records log data every 50ms on various parameters. This information was used as a part of overall system QA to evaluate the different parts of VMAT system. Two sets of DynaLog -iles were created separately by the Clinac and the MLC controller. The Clinac DynaLog -ile contains both the planned cumulative MU versus gantry angle and the actual cumulative MU delivered versus the actual gantry angle. The MLC DynaLog -iles contain expected and actual leaf positions (22, 23) . The mean standard deviations in MU and gantry angle and average root mean square (RMS) of the deviations of leaves were compared for the various gated deliveries of ten patients to know the performance of machine under different gated deliveries.
COMPASS 3D dosimetry
For veri-ication of gated delivery, VMAT plans along with patient's CT scan, structure set and 3D dose planes were exported to COMPASS in DICOM RT format. MatriXX Evolution along with 5 cm RW3 buildup plates and gantry angle sensor was placed on linear accelerator using a gantry holder mount (-igure 2b) (source to detector distance of 76.2 cm). On treatment machine, dose response was measured by COMPASS using MatriXX Evolution . The infrared re-lecting box placed on couch was periodically moved to provide gating signal for RPM system. The response of detector was measured in movie Table 1 shows the average gamma agreement index (GAI) of 10 patients. GAI is de-ined as percentage of points passing the gamma evaluation criteria. Gamma analyses between Eclipse TPS calculated and MatriXX Evolution measured, criteria was set as 3mm DTA and 3% DD. For statistical analyses, non-gated was kept as reference. In TPS vs G-VMAT, p value calculated between non-gated and PGWL of 80%, 50%, 30% and 20% were 0.755, 0.133, 0.072 and 0.111 respectively. There was not much statistical signi-icant difference in GAI of four different gated VMAT dose deliveries. Gamma analysis were performed between non-gated measurement and gated measurement. As measurement setup remains unchanged and in order to appreciate the subtle difference in dose delivery between four PGWL, gamma calculating criteria was set stringent by reducing to 1mm DTA and 1% DD. GAI for reproducibility test was more than 99% and found to be statically insigni-icant (p-value ~1).
RESULTS

2D Planar dosimetry
Results show that all experiments ended with results within acceptability criteria of GAI larger than 95%.
VMAT dynaLog !iles
For 10 patient's -ive different deliveries, both the Clinac and MLC DynaLog -iles were recorded to assess the machine performance. The mean standard deviations between actual and expected values of the delivered MU and the gantry position were listed in table 1. Average error RMS of all MLC positions for different phase gating was reported in table 1. Figure 4 shows the 10 patients average percentage of leaf position errors for -ive different phases. The Clinac log -ile analysis showed good agreement between planned cumulative dose delivered MU versus gantry angle and the actual cumulative dose delivered MU versus gantry angle. For all different phase gating window level, the STDVs MU and gantry position were less than 0.10 MU and 0.33° respectively and showed no visual signi-icant difference. Analysis of the MLC log -ile indicated good agreement in the actual leaf positions with respect to the planned positions. The RMS of the deviations of all leaves were less than 0.58 mm. There were no systematic drifts in the MU, gantry and MLC positions for different phase gating window level. However there was marginal increase in percentage of MLC error counts for 0.00-0.05mm with respect to decrease in gating window level.
COMPASS 3D dosimetry
In table 2, percentage difference of average dose, percentage difference of D95 and D1 and average 3D gamma between Eclipse TPS calculated and COMPASS measured for PTV's and critical OAR's were listed. Figure 5 shows the dose difference between calculated and measured for PGWL 50% along with DVH comparison. For PTV, irrespective of duty cycle, percentage difference of D95 was less than 3%. For Spinal cord D1 percentage difference was found to be less than 2%. For lungs, percentage difference of average dose was more than 3% which was slightly more than normal clinical range, whereas for all other structures percentage difference was less than 2% which was clinically insigni-icant. The higher difference in lung was primarily due to difference in algorithm. The dose calculation algorithm in an inhomogeneous medium was completely different in Eclipse TPS and COMPASS 3D dosimetry system. The COMPASS uses CCC/S algorithm, where the dose calculation is based primarily on a point source dose spread array. The Eclipse TPS uses AAA where dose calculation is based on a pencil beam in association with lateral density scaling. In CCC/S, the dose at a point from a point source of given TERMA (total energy released per unit mass) to the dose at another location in a patient can be calculated by scaling both primary and scatter. Point to point density scaling of this kind is not feasible by the pencil beam kernel method. The point spread kernel based method allows greater -lexibility in dealing with 3D inhomogeneous medium than pencil beam kernel. The point kernel-based algorithms (CCC/ S) are superior to the pencil beam kernel method (AAA) in handling inhomogeneous region. COMPASS in its current implementation, could measure the delivered dose with suf-icient accuracy and could project the 3D dose distribution directly on the patient's CT scan. 
DISCUSSION
Gated VMAT dose measurements were compared with TPS calculated dose distribution (performed without gating) and non-gated dose measurement to appraise the dosimetric impact of the presence of gating in VMAT dose delivery. We have measured four different phase gating window level of 80%, 50%, 30% and 20% (-igure 1). The treatment delivery time of gated VMAT was longer than that of non-gated VMAT, for window level 20% the treatment delivery time was increased by factor of 5. But in a clinical treatment the gating window level will be placed around 30%-75% by considering reasonable total treatment time (2) . The window level 20% has more than 20 interruptions per arc. The highest number of interruptions means highest potential problems with gantry inertia at release from beam-hold and all possible related mechanical and electronic consequences (12) . The results have showed good agreement between TPS calculation and measurement for even very small window level of 20%. Varian RPM system assumes that the motion of external markers correlates with the tumor motion. In this study we did not address the issue of whether respiratory gating signal is appropriate to surrogate internal organ motion. Our primary intent was to assess machine reliability in delivering gated VMAT. Due to this MatriXX Evolution detector was -ixed in a phantom for both 2D planar dosimetry and COMPASS 3D dosimetry while infrared re-lecting box was periodically moved to provide gating signal for RPM (-igure 2a and 2b). This setup was used to eliminate the uncertainties linked to the accuracy of moving supports and on the synchronization between detector position and gate-open phase.
2D planar dosimetry results show that for all measurements the GAI were larger than clinical acceptability criteria of 95% (12, 24) . In spite of reducing gamma calculating criteria to 1mm DTA and 1% DD, there was not much signi-icant difference in GAI between gated and non-gated VMAT dose delivery. Even for 20% phase gating window level, which has highest number of interruptions, the value was 98.9% ± 0.9. For Dynalog -iles, our values were found to be correlating with Nicolini et al. (12) and Teke et al. (22) as there are no other internationally acceptable reference values. The extensive analysis of the log -iles has con-irmed the delivery accuracy of gated VMAT treatments. Implementation of patient-speci-ic QA for VMAT was strongly recommended because of the complexity of irregular -ield shapes, small--ield dosimetry and time-dependent leaf sequences. Adding gating (beam holds) to VMAT increases the complexity further. Therefore it is important to evaluate the feasibility and the dosimetric accuracy of the gated VMAT before its clinical use (1, 5) . The gamma agreement index in table 1 does not provide any clinically relevant information about the results (13) , whereas COMPASS system provides the signi-icance of error in PTV and as well as in OAR's (14) (15) (16) (17) (18) . The information provided by DynaLog -iles and traditional 2D planar dosimetry cannot easily be translated onto dose deviations in the tumor and/or at OAR's. However, Qian et al. (25) have able the reconstruct dose in patient CT scan using trajectory log -iles from Varian true beam machine, in-house Matlab program and Eclipse TPS for dose veri-ication of respiratory-gated VMAT. On other hand, the advantage of COMPASS 3D dosimetry system over other QA systems was its capability of performing independent 3D dose reconstruction on patient CT scan using beam model, detector measurement and treatment plan. Literatures have validated the accuracy of dose reconstruction method in COMPASS and proved that COMPASS was adequate to perform QA of IMRT/VMAT treatment (14) (15) (16) (17) (18) (19) . Collapsed cone convolution/superposition algorithm based dose calculation engine in COMPASS system, computes dose distribution in heterogeneous medium (lung) similar to Monte Carlo simulations (20) . DVH based evaluation will be a good alternative since it allows physicist and physician to accept or reject the treatment plan based on the dose difference in PTV and OAR's (-igure 5). The results from table 2 shows that 3D dose parameters for ten patients measured for different phase gating window level were well within the clinically acceptable tolerance level of ±5% (24, 26) . The average 3D gamma for PTV's and OAR's for ten patients used in this study were less than the recommended value of 0.6 by Visser et al. (18) . Due to low dose in contralateral lung the percentage difference of average dose was slightly more than ipsilateral lung.
CONCLUSION
The results from this study show that gated VMAT delivery provided dose distributions equivalent to non-gated delivery to within clinically acceptable limits. In 2D planar there is a lack of correlation between performance gamma passing rates and dose errors in anatomic regions-of-interest. Advantage of COMPASS is that it provides the clinical relevance of dose discrepancies between measured and TPS calculated. This study shows that new independent 3D COMPASS QA system can used to ensure the accuracy of gated VMAT treatment delivery.
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